Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

906.17 -0.01 (-0.00%)
Streaming Delayed Price Updated: 11:39 AM EDT, Sep 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 424,722
Open 906.31
Bid (Size) 906.17 (2)
Ask (Size) 906.96 (2)
Prev. Close 906.18
Today's Range 903.46 - 910.82
52wk Range 516.57 - 972.53
Shares Outstanding N/A
Dividend Yield 0.50%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
This Small-Cap Stock Has a Promising GLP-1 Drug Which Could Rival Novo Nordisk and Eli Lilly's Weight-Loss Treatments
Terns has a modest market cap of less than $800 million, and its possible upside could be massive. 
Via The Motley Fool
ADX: A High-Yielding, Diversified CEF Worth Looking Into
When it comes to investing, there are two critical “bedrocks” we need to keep in mind. These two facts are why 95% of my favorite high-income investments, closed-end funds (CEFs), have made investors... 
Via Talk Markets

Performance

YTD
+53.02%
+53.02%
1 Month
-1.70%
-1.70%
3 Month
+1.65%
+1.65%
6 Month
+17.26%
+17.26%
1 Year
+58.62%
+58.62%

More News

Read More
Looking Into Eli Lilly's Recent Short Interest
Via Benzinga
Unpacking the Latest Options Trading Trends in Eli Lilly
Via Benzinga
Prediction: This Will Be the First Healthcare Stock to Join the Trillion-Dollar Club
Via The Motley Fool
1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc)
Via The Motley Fool
6 Incredible Reasons to Invest in Eli Lilly
Via The Motley Fool
Looking At Eli Lilly's Recent Unusual Options Activity
Via Benzinga
Eli Lilly Scores FDA Approval For Eczema Treatment Ebglyss
Via Benzinga
Exposures Product Safety
Kalm Therapeutics Hires Former GSK Director Dr. Tomoko Maeda-Chubachi as Chief Medical Officer
Via Newsfile
3 Stocks to Buy and Hold Forever
Via The Motley Fool
Time To Invest And Or Trade In Bio-Tech Stocks?
Via Talk Markets
Topics ETFs
Stock Market Rally Revives; Apple iPhone 16, Nvidia, Oracle, Adobe In Focus: Weekly Review
Via Investor's Business Daily
Unpacking the Latest Options Trading Trends in Eli Lilly
Via Benzinga
Eli Lilly Pumps $800M Into Irish Operations To Meet Skyrocketing Demand For Mounjaro, Zepbound
Via Benzinga
Forget Eli Lilly and Novo Nordisk: This Could Be the Best Weight Loss Stock to Buy Right Now
Via The Motley Fool
3 No-Brainer Biotech Stocks to Buy With $200 Right Now
Via The Motley Fool
Why Roche Holdings Stock Withered on Wednesday
Via The Motley Fool
Why Viking Therapeutics Stock Rocked the Market Today
Via The Motley Fool
Harvest ETFs (TSX: LLYH, LLYH.U, AMZH, AMZH.U, MSFH, MSFH.U, NVDH, NVDH.U, LLHE, LLHE.U, AMHE, AMHE.U, MSHE, MSHE.U, NVHE, NVHE.U ) Closes the Market
Via Newsfile
Topics ETFs
4 No-Brainer Stock Splits to Buy Now
Via The Motley Fool
Could Elon Musk Become The World's First Trillionaire? Tesla's Success Could Make It Happen As Early As...
Via Benzinga
Novo Nordisk Jumps After New Weight-Loss Pill Tops Wegovy; Eli Lilly, Viking Shares Rise
Via Investor's Business Daily
Ozempic Maker Novo Nordisk Touts Encouraging Data From New Obesity Pill Showing Double Weight Loss Compared To Wegovy
Via Benzinga
Forget Mounjaro: 1 Reason Investors Should Love Eli Lilly Stock Even More (Hint: I'm Not Talking About Zepbound)
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.